1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
    + Filter
    Loading...
    Custom Services order now ship next day

    Met

    Loading...

    Anti-MET Products

    • Anti-Human Met(Onartuzumab) (TAB-190-F(E))
      • Derivation: Humanized (from mouse)
      • Species Reactivity: Human
      • Type: Fab / Fc - G1 - kappa
      • Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
      Go to compare Compare
    More Infomation

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Creative Biolabs offers advanced recombinant antibodies specifically designed to target MET, catering to the needs of biomedical researchers. We strive to support scientific progress by providing high-quality recombinant products known for their superior performance. Alongside exceptional value, we offer comprehensive technical support to help researchers achieve optimal outcomes. By utilizing our MET antibodies, you equip your studies with reliable tools that drive impactful discoveries and further advancements in biomedical science.

    MET: A Crucial target in Cancer and Tumor growth

    MET (mesenchymal-epithelial transition factor) is a receptor tyrosine kinase that plays a critical role in various cellular processes, including growth, survival, and differentiation. Activated by its ligand, hepatocyte growth factor (HGF), MET signaling regulates embryonic development, tissue regeneration, and wound healing. Aberrant MET expression or activation is associated with multiple cancers, contributing to tumor growth, metastasis, and resistance to therapies. Due to its pivotal role in oncogenesis, MET has emerged as a valuable therapeutic target, with ongoing research focusing on understanding its mechanisms and developing targeted therapies to inhibit its dysregulated activity in diseases.

    Alternative Names

    DA11; HGFR; AUTS9; RCCP2; c-Met; DFNB97

    Background

    This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers.

    Protein class

    Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, RAS pathway related proteins

    Predicted location

    Intracellular, Membrane, Secreted (different isoforms)

    Single cell type specificity

    Cell type enhanced (Glandular and luminal cells, Prostatic glandular cells, Urothelial cells, Alveolar cells type 2, Club cells, Pancreatic endocrine cells)

    Immune cell specificity

    Not detected in immune cells

    Cell line specificity

    Cell line enhanced (A-431, CAPAN-2)

    Interaction

    Heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when phosphorylated with downstream effectors including STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1, SPSB2 and SPSB4 (By similarity). Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction. Interacts with MUC20; prevents interaction with GRB2 and suppresses hepatocyte growth factor-induced cell proliferation. Interacts with GRB10. Interacts with PTPN1 and PTPN2. Interacts with LECT2; this interaction may have an antagonistic effect on receptor activation (PubMed:27334921). Interacts with HSP90AA1 and HSP90AB1; the interaction suppresses MET kinase activity (PubMed:26517842). (Microbial infection) Interacts via extracytoplasmic residues 25-656 with L.monocytogenes InlB; MET can bind HGF, its endogenous ligand, and InlB simultaneously (PubMed:11081636, PubMed:17662939). InlB probably dimerizes upon binding to MET, which encourages subsequent dimerization of MET (Probable).

    Molecular function

    Kinase, Receptor, Transferase, Tyrosine-protein kinase

    More Types Infomation

    Anti-MET rAb Products

    We offer premium anti-MET recombinant antibody products designed to support and advance biological research efforts, facilitating the exploration and discovery of the MET target with exceptional reliability.

    Cat. No. Product Name Target Species Host Species Applications
    TAB-521CL Anti-Human MET Recombinant Antibody (ABT-700) Human Human WB; FuncS
    HPAB-0030-WJ Human Anti-MET Recombinant Antibody Human; Mouse Human ELISA; WB
    PABL-271 Human Anti-MET Recombinant Antibody (clone 5D5) Human Human WB; Block; FuncS
    TAB-009MZ Human Anti-MET Recombinant Antibody Human; Mouse Human ELISA; FC; MTS assay
    TAB-538LC Human Anti-MET Recombinant Antibody Human Human Inhib

    Creative Quality Control

    To meet customer expectations, we have implemented a rigorous quality management system that ensures the excellence of our products while providing reliable and professional technical support, empowering researchers with the tools needed to achieve their scientific goals.

    Fig.1 SDS-PAGE analysis of PABL-271. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-MET antibody
    (Cat# PABL-271, Creative Biolabs).

    Fig.2 SEC-HPLC analysis of PABL-271. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-MET antibody
    (Cat# PABL-271, Creative Biolabs).

    Fig.3 ELISA analysis of PABL-271. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-MET antibody
    (Cat# PABL-271, Creative Biolabs).

    Fig.4 WB analysis of PABL-271. (Creative Biolabs Original)Fig.4 WB analysis of anti-MET antibody
    (Cat# PABL-271, Creative Biolabs).

    Fig.5 DB analysis of PABL-271. (Creative Biolabs Original)Fig.5 DB analysis of anti-MET antibody
    (Cat# PABL-271, Creative Biolabs).

    Customer Reviews

    Excellent
    Ca**y
    Anti-Human MET Recombinant Antibody (ABT-700) (Cat#: TAB-521CL)
    The Anti-Human MET Recombinant Antibody (ABT-700) proved highly effective in my research, where I used it for Western blot and functional assays. It displayed outstanding specificity, accurately identifying MET expression in cell lysates. Moreover, its ability to inhibit MET activity in functional assays highlighted its reliability for exploring MET-related signaling mechanisms, making it indispensable for my study.
    13/Dec/2022
    Excellent
    O**v*a
    Human Anti-MET Recombinant Antibody (clone 5D5) (Cat#: PABL-271)
    I used the Human Anti-MET Recombinant Antibody (clone 5D5) in my research for Western blotting and blocking assays. It delivered precise and consistent detection of MET expression and effectively blocked MET signaling pathways. These results provided critical insights into MET's role in cell signaling, significantly advancing my understanding of its biological functions.
    9/Jul/2023
    Excellent
    Da**el
    Human Anti-MET Recombinant Antibody (Cat#: TAB-009MZ)
    In my study, the Human Anti-MET Recombinant Antibody played a pivotal role in detecting MET expression. Using ELISA and flow cytometry, the antibody showcased exceptional sensitivity and accuracy, delivering reliable data on MET-positive cells. These findings significantly deepened my insights into MET's involvement in cellular mechanisms and disease pathology.
    28/Mar/2022

    rAb Production

    With extensive experience in recombinant antibody production and optimization, we ensure that our services meet the highest quality standards. By delivering top-tier antibody products promptly, we support your research with reliable and efficient solutions, tailored to your specific scientific needs.

    Featured Anti-MET Recombinant Antibody Production PlatformsFig.6 Anti-MET recombinant antibody production: milligram-scale. (Creative Biolabs Original)
    Fig.6 Milligram-scale recombinant antibody production.

    Fig.7 Anti-MET recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.7 Gram-scale recombinant antibody production.

    rAb Modalities

    Creative Biolabs offers a wide selection of premium antibody formats to meet the varied needs of our customers. These formats encompass full-length antibodies, VH fragments, Fab, scFv, and more, providing flexible options for different research applications.

    Fig.8 Diverse anti-MET recombinant antibody production and modalities. (Creative Biolabs Original)Fig.8 Full Length Anti-MET Recombinant Antibody Production and Modalities.

    Drug Information Targeting MET

    Table 1. Therapeutic approaches targeting MET in clinical development.

    Research phase Company Classification Indications Details
    Launched - 2019 Chugai Pharmaceutical Drug Conjugates Chronic lymphocytic leukemia This is a MET-targeted antibody-drug conjugate comprising an anti-MET monoclonal antibody and a monomethyl auristatin E (MMAE)-based payload.
    Phase II Hangzhou Huadong Medicine Group Biologics Autoimmune disease It is a bispecific humanized diabody targeting both CD32B and MET, is in phase II development at Provention Bio (now Sanofi) for the treatment of systemic lupus erythematosus.
    Phase I Janssen Biologics Chronic lymphocytic leukemia This is a T-cell redirecting tri-specific antibody developed by Janssen, is in early clinical development in an injectable subcutaneous formulation for the treatment of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Phase I Genentech Drug Conjugates Non-Hodgkin lymphoma It is an antibody drug conjugate had been in phase I clinical trials for the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma; however no recent developments have been reported.

    If you would like further information about our anti-MET recombinant antibody products, feel free to contact us. Our expert team is ready to assist with any questions you may have. We look forward to building a collaborative partnership that advances your research objectives.

    Related Diseases
    EGFR Tyrosine Kinase Inhibitor Resistance EGFR Tyrosine Kinase Inhibitor Resistance
    Go to compare

    Go to compare